AI-generated analysis. Always verify with the original filing.
On February 13, 2026, Opus Genetics, Inc. entered into a securities purchase agreement, constituting a private placement. On February 18, 2026, the Company filed a Certificate of Designation of Preferences, with related unaudited information furnished under Item 2.02.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. Private Placement On February 13, 2026, Opus Genetics, Inc. (the “Company”) entered into a securities purchase agree
is unaudited and subject to adjustment. The information contained in this Current Report on Form 8-K is being furnished and shall not be deemed to be “filed” fo
. Unregistered Sales of Equity Securities. The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item
. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On February 18, 2026, the Company filed a Certificate of Designation of Preferences,
. Other Events. The information set forth in Item 2.02 of this Current Report on Form 8-K is incorporated by reference into this Item 8.01. Item 9.01 Financial